Similar Papers

Paper Title
Journal
Date
Author
Decision letter: TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs
Benny Chain ... Aleksandra M Walczak
-
Benny Chain, et. al.Benny Chain ... Aleksandra M Walczak
04 May 2021
Editor's evaluation: TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs
Benny Chain
-
Benny ChainBenny Chain
04 May 2021
Expanding the split-pool combinatorial barcoding toolkit to characterize the effects of aging in mouse TCR diversity.
Efthymia Papalexi ... Charles Roco
The Journal of Immunology | VOL. 212
Efthymia Papalexi, et. al.Efthymia Papalexi ... Charles Roco
01 May 2024
Editor's evaluation: Improved T cell receptor antigen pairing through data-driven filtering of sequencing information from single cells
K Christopher Garcia
-
K Christopher GarciaK Christopher Garcia
11 Oct 2022
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.